Royal Bank of Canada
MBRX icon

Royal Bank of Canada’s Moleculin Biotech MBRX Stock Holding History

Royal Bank of Canada’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Hold
0
– – – 7424
2025
Q3 		– Hold
0
– – – 7347
2025
Q2 		– Hold
0
– – – 7213
2025
Q1 		– Hold
0
– – – 7069
2024
Q4 		– Hold
0
– – – 7096
2024
Q3 		– Hold
0
– – – 7189
2024
Q2 		– Hold
0
– – – 7342
2024
Q1 		– Sell
-54
Closed -$11.5K – 7346
2023
Q4 		$17K Buy
54
+53
+5,300% +$11K ﹤0.01% 6361
2023
Q3 		$0 Sell
1
-2
-67% -$413 ﹤0.01% 7361
2023
Q2 		$1K Buy
+3
New +$792 ﹤0.01% 7035
2022
Q4 		– Sell
-1
Closed – – 7515
2022
Q3 		$0 Buy
+1
New +$579 ﹤0.01% 7675
2020
Q4 		– Hold
0
– – – 7195
2020
Q3 		– Hold
0
– – – 6805
2020
Q2 		– Sell
-1
Closed -$2.37K – 6784
2020
Q1 		$1K Hold
1
– – ﹤0.01% 6457
2019
Q4 		$2K Hold
1
– – ﹤0.01% 6561
2019
Q3 		$2K Buy
+1
New +$2.58K ﹤0.01% 6291
2019
Q2 		– Hold
0
– – – 6716
2019
Q1 		– Hold
0
– – – 6659
2018
Q4 		– Hold
0
– – – 6586
2018
Q3 		– Hold
0
– – – 6522

Other funds holding MBRX

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EI
EFG International Zurich $4.67B AUM
PWPS
Pinnacle Wealth Planning Services Mansfield, Ohio $968M AUM 19.1% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return

Royal Bank of Canada's MBRX Position: Q4 2025 in Review

Royal Bank of Canada held its Moleculin Biotech (MBRX) position steady in Q4 2025 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7424.

Royal Bank of Canada first reported a position in MBRX in Q3 2019 and has held it in 7 quarters since. The position peaked at $17K in Q4 2023. 17 funds tracked by Wall St. Rank hold MBRX as of Q4 2025.

  • Royal Bank of Canada held 0 shares of Moleculin Biotech worth $0 as of Q4 2025.
  • Royal Bank of Canada left its Moleculin Biotech share count unchanged in Q4 2025.
  • Moleculin Biotech made up ﹤0.01% of Royal Bank of Canada's portfolio in Q4 2025, its #7424 holding.
  • Royal Bank of Canada first reported a position in Moleculin Biotech in Q3 2019 and has held it in 7 quarters since.
  • Royal Bank of Canada's Moleculin Biotech position peaked at $17K in Q4 2023.
  • 17 funds tracked by Wall St. Rank held Moleculin Biotech as of Q4 2025.

Based on Royal Bank of Canada's 13F filing for Q4 2025, filed 17 Feb 2026.